CA2496538A1 - Boronic ester and acid compounds, synthesis and uses - Google Patents
Boronic ester and acid compounds, synthesis and uses Download PDFInfo
- Publication number
- CA2496538A1 CA2496538A1 CA002496538A CA2496538A CA2496538A1 CA 2496538 A1 CA2496538 A1 CA 2496538A1 CA 002496538 A CA002496538 A CA 002496538A CA 2496538 A CA2496538 A CA 2496538A CA 2496538 A1 CA2496538 A1 CA 2496538A1
- Authority
- CA
- Canada
- Prior art keywords
- aryl
- alkyl
- 10aryl
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Disclosed herein are novel boronic ester and acid compounds, their synthesis and their uses.
Claims (166)
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH), -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-or-CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, aryl, alkoxy or aryloxy;
R1 at each occurence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1;
provided that the compound is other than isovaleryl-phenylalanine-norvaline-[(naphthylmethyl),(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)]methylamide, (3-t-butylsulfonyl)propionyl-norvaline-(1-naphthyl, dihydroxyboryl)methylamide or (3-t-butylsulfonyl)propionyl-norvaline-(1-naphthylmethyl),(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-
or a pharmaceutically acceptable salt thereof, wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH), -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-or-CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, aryl, alkoxy or aryloxy;
R1 at each occurence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1;
provided that the compound is other than isovaleryl-phenylalanine-norvaline-[(naphthylmethyl),(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)]methylamide, (3-t-butylsulfonyl)propionyl-norvaline-(1-naphthyl, dihydroxyboryl)methylamide or (3-t-butylsulfonyl)propionyl-norvaline-(1-naphthylmethyl),(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-
2-yl)]methylamide.
2. The compound of claim 1, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, then R7 can also be saturated or partially saturated heterocycle.
2. The compound of claim 1, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, then R7 can also be saturated or partially saturated heterocycle.
3. The compound of claim 1, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10 aryl, C6-10ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5-to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
4. The compound of claim 1, wherein B1 is CH, and X1 and X2 are each -C(O)-NH-.
5. The compound of claim 1, wherein R1 and R2 are independently selected from the group consisting of alkyl and -CH2-R5, where R5 is one of C6-10 aryl, C1-10 alk(C6-10)aryl, C3-10 cycloalkyl, or a 5-, 6-, 9- or 10-membered heterocycle.
6. The compound of claim 1, wherein R2 is quinolinylmethyl.
7. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-(CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-,-SO2-NH-,-SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy and aryloxy;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is independently one of aryl, aralkyl, alkaryl, cycloalkyl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or-W-R6, where W is a chalcogen and R6 is alkyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-(CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-,-SO2-NH-,-SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy and aryloxy;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is independently one of aryl, aralkyl, alkaryl, cycloalkyl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or-W-R6, where W is a chalcogen and R6 is alkyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
8. The compound of claim 7, wherein the nitrogen-containing ring system is selected from the group consisting of:
9. The compound of claim 7, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7 -C(O)-, then R7 can also be saturated or partially saturated heterocycle.
10. The compound of claim 9, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10aryl, C6-10ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5-to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
11. The compound of claim 7, wherein B1 is CH, and X1 and X2 are each -C(O)-NH-.
12. The compound of claim 7, wherein R1 and R2 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9- or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
13. The compound of claim 7, wherein P is hydrogen.
14. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms, together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, aryl, alkoxy and aryloxy;
R1 at each occurrence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, Cl-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is where R9 is one of cycloalkyl, aryl, aralkyl, heteroaryl, heteroaryalkyl, or alkyl which is substituted with one of C1-6 alkyl, halogen, monohalo (C1-6) alkyl, and trifluoromethyl; and wherein said cycloalkyl,aryl, aralkyl, heteroaryl and heteroarylalkyl groups can be optionally substituted with one or two of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
A1 and A2 are independently one of hydrogen, halogen, C1-6 alkyl, monohalo(C1-6)alkyl, or trifluoromethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms, together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, aryl, alkoxy and aryloxy;
R1 at each occurrence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, Cl-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is where R9 is one of cycloalkyl, aryl, aralkyl, heteroaryl, heteroaryalkyl, or alkyl which is substituted with one of C1-6 alkyl, halogen, monohalo (C1-6) alkyl, and trifluoromethyl; and wherein said cycloalkyl,aryl, aralkyl, heteroaryl and heteroarylalkyl groups can be optionally substituted with one or two of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
A1 and A2 are independently one of hydrogen, halogen, C1-6 alkyl, monohalo(C1-6)alkyl, or trifluoromethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
15. The compound of claim 14, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, then R7 can also be saturated or partially saturated heterocycle.
16. The compound of claim 14, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5- to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
17. The compound of claim 14, wherein X1 and X2 are each -C(O)-NH-.
18. The compound of claim 14, wherein one of R1, R2 or R3 is where A1 and A2 are independently one of hydrogen, C1-6 alkyl, halogen, monohalo (C1-6) alkyl or trifluoromethyl;
R9 is one of C3-10 cycloalkyl, C6-10 aryl, C6-10 ar(C1-6)alkyl, a 5- to 10-membered heteroaryl or a 5- to 10-membered heteroaryl(C1-6)alkyl;
and the remaining R1, R2 and R3 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9 or 10- membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9- or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino.
dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl; C6-10 aryl(C1-6)alkoxy,hydroxy; C1-6 alkylthio;
C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
R9 is one of C3-10 cycloalkyl, C6-10 aryl, C6-10 ar(C1-6)alkyl, a 5- to 10-membered heteroaryl or a 5- to 10-membered heteroaryl(C1-6)alkyl;
and the remaining R1, R2 and R3 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9 or 10- membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9- or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino.
dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl; C6-10 aryl(C1-6)alkoxy,hydroxy; C1-6 alkylthio;
C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
19. A pharmaceutical composition, comprising a compound of any one of claims 1, 7, or 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
20. A pharmaceutical composition, comprising a compound of claim 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
21. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or-CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or-CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
22. The compound of claim 21, wherein P is R7-C(O)-, and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
23. The compound of claim 21, wherein R3 is isobutyl.
24. The compound of claim 21, wherein Z1 and Z2 are independently one of hydroxy, C1-6 alkoxy, or C6-10 aryloxy.
25. The compound of claim 24, wherein Z1 and Z2 are both hydroxy.
26. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;~
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 and R2 are each independently -CH2-R5, where R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, or -W-R6, where W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, or alkaryl in R1, R2 and R5 can be optionally substituted by one or two substitutes independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C1-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C1-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;~
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 and R2 are each independently -CH2-R5, where R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, or -W-R6, where W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, or alkaryl in R1, R2 and R5 can be optionally substituted by one or two substitutes independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C1-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C1-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
27. The compound of claim 26, wherein P is R7-C(O)-, and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
28. The compound of claim 26, wherein R3 is isobutyl.
29. The compound of claim 26, wherein Z1 and Z2 are independently one of hydroxy, C1-6 alkoxy, or C6-10 aryloxy.
30. The compound of claim 26, wherein Z1 and Z2 are both hydroxy.
31. The compound of claim 26, wherein R5 is C6-10 aryl.
32. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- and R7 is pyrazinyl;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle, and -CH2R5, where R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, or -W-R6, where W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, or alkaryl in R1, R2 and R5 can be optionally substituted by one or two substitutes independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- and R7 is pyrazinyl;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle, and -CH2R5, where R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, or -W-R6, where W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, or alkaryl in R1, R2 and R5 can be optionally substituted by one or two substitutes independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R3 is C4 alkyl;
Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
33. ~A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen;
R1 is -CH2-R5, where R5 is C6-10 aryl;
R2 is benzyl;
R3 is C4 alkyl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof, wherein:
P is R7-C(O)- or R7-SO2-, and R7 is heteroaryl or a saturated or partially unsaturated heterocycle;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen;
R1 is -CH2-R5, where R5 is C6-10 aryl;
R2 is benzyl;
R3 is C4 alkyl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
34. ~The compound of claim 33, wherein P is R7-C(O)-, and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
35. ~The compound of claim 33, wherein P is 2-pyrazinecarbonyl.
36. ~The compound of claim 33, wherein R3 is isobutyl.
37. ~The compound of claim 33, wherein R5 is phenyl.
38. ~The compound of claim 33, wherein Z1 and Z2 are both hydroxy.
39. ~A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
P is 2-pyrazinecarbonyl;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen;
R1 is -CH2-R5, where R5 is phenyl;
R2 is benzyl;
R3 is isobutyl; and Z1 and Z2 are both hydroxy.
or a pharmaceutically acceptable salt thereof, wherein:
P is 2-pyrazinecarbonyl;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen;
R1 is -CH2-R5, where R5 is phenyl;
R2 is benzyl;
R3 is isobutyl; and Z1 and Z2 are both hydroxy.
40. ~Use of a therapeutically effective amount of a compound to treat cancer in a patient in need thereof, wherein said compound is of the formula:
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
41. ~The use according to claim 40, wherein P is R'-C(O)- or R'-O-C(O)- and R7 is alkyl, cycloalkyl, aryl or aralkyl.
42. ~The use according to claim 41, wherein P is acetyl, benzoyl, benzyloxycarbonyl or tert-butoxycarbonyl.
43. ~The use according to claim 40, wherein P is R7-C(O)-, and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
44. ~The use according to claim 40, wherein R3 is isobutyl.
45. ~The use according to claim 40, wherein R2 is naphthylmethyl.
46. ~Use of a therapeutically effective amount of N-acetyl-L-leucine-.beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid, or a pharmaceutically acceptable salt or boronate ester thereof, to treat cancer in a patient in need thereof.
47. ~The use according to claim 40, further comprising the use of a tumoricidal agent selected from the group consisting of cytotoxic drugs and radiation.
48. ~A compound having the formula:
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10ary1(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10ary1(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
49. The compound of claim 48, wherein P is R7-C(O)- or R7-O-C(O)- and R7 is alkyl, cycloalkyl, aryl or aralkyl.
50. The compound of claim 49, wherein P is acetyl, benzoyl, benzyloxycarbonyl or tert-butoxycarbonyl.
51. The compound of claim 48, wherein P is R7-C(O)-, and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
52. The compound of claim 48, wherein R3 is isobutyl.
53. ~The compound of claim 48, wherein R2 is naphthylmethyl.
54. ~A compound which is N-Acetyl-L-leucine-.beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid or a pharmaceutically acceptable salt or boronate ester thereof.
55. ~A pharmaceutical composition comprising a compound of claim 48, or a pharmaceutically acceptable salt or boronate ester thereof, and a pharmaceutically acceptable carrier or diluent.
56. ~Use of an effective amount of a compound according to claim 48 to reduce the rate of muscle protein degradation in a cell.
57. ~Use of an effective amount of a compound according to claim 48 to reduce the activity of NF-.KAPPA.B in a cell.
58. ~Use of an effective amount of a compound according to claim 48 to reduce the rate of intracellular protein breakdown.
59. ~Use of an effective amount of a compound according to claim 48 for the prevention or treatment of an inflammatory condition in a patient in need thereof.
60. ~Use of an effective amount of a proteasome inhibitor to inhibit HIV
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof; wherein P is an amino protecting group;
A is 1;
B1 is CH;
X1 is -C(O)-NH-;
X2 is -C(O)-NH-;
R is hydrogen or alkyl;
R1 is hydrogen, C1-8 alkyl, C3-10 cycloalkyl, C6-10 aryl, or -CH2-R5, where the ring portion of said aryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R2 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
R3 is C4 alkyl;
R5 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl; and Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
61. The use according to claim 60, wherein P is R7-C(O)- or R7-O-C(O)- and R7 is alkyl, cycloalkyl, aryl or aralkyl.
62. The use according to claim 61, wherein P is acetyl, benzoyl, benzyloxycarbonyl or tert-butoxycarbonyl.
63. The use according to claim 60, wherein P is R7-C(O), and R7 is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.
64. The use according to claim 60, wherein R3 is isobutyl.
65. The use according to claim 60, wherein R2 is naphthylmethyl.
66. Use of an effective amount of N-acetyl-L-leucine-.beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid, or a pharmaceutically acceptable salt or boronate ester thereof, to inhibit HIV
replication in an animal in need thereof.
replication in an animal in need thereof.
67. A compound of the structure:
or a pharmaceutically acceptable salt thereof; wherein P is R7-C(O)-, R7-NH-C(O)-, R7-O-C(O)-, or R7-SO2-, where R7 is heteroaryl or heteroarylalkyl; or when P is R7-C(O), R7 can also be N-morpholinyl;
B1, at each occurrence, is independently one of N or CH;
X1 at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is selected from the group consisting of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi-, or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aralkyl, alkoxy or aryloxy;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or W-R6, W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
or a pharmaceutically acceptable salt thereof; wherein P is R7-C(O)-, R7-NH-C(O)-, R7-O-C(O)-, or R7-SO2-, where R7 is heteroaryl or heteroarylalkyl; or when P is R7-C(O), R7 can also be N-morpholinyl;
B1, at each occurrence, is independently one of N or CH;
X1 at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is selected from the group consisting of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi-, or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aralkyl, alkoxy or aryloxy;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or W-R6, W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 1.
68. The compound of claim 67, wherein the heteroaryl group in R7 is selected from the group consisting of thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzylfuranyl, benzoxazolyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, .beta.-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl.
69 The compound of claim 67, wherein P is one of quinolinecarbonyl, pyridinecarbonyl, quinolinesulfonyl, quinoxalinecarbonyl, quinoxalinesulfonyl, pyrazinecarbonyl, pyrazinesulfonyl, furancarbonyl, furansulfonyl, or N-morpholinylcarbonyl.
70. The compound of claim 67, wherein P is one of 8-quinolinecarbonyl, 8-quinolinesulfonyl, 2-quinoxalinecarbonyl, 2-quinoxalinesulfonyl, 2-pyrazinecarbonyl, 2-pyrazinesulfonyl, 3-furancarbonyl, 3-furansulfonyl, or N-morpholinylcarbonyl.
71. The compound of claim 67, wherein B1, at each occurrence, is CH.
72. The compound of claim 71, wherein X1, at each occurrence, is -(CO)-NH-.
73. The compound of claim 72, wherein X2 is -(CO)-NH-.
74. The compound of claim 67, wherein R is hydrogen or C1-8 alkyl.
75. The compound of claim 67, wherein:
R1, at each occurrence, and R2 and R3 are each independently on of hydrogen, C1-8alkyl, C3-10 cycloalkyl, C6-10 aryl, a 5-, 6-, 9- or 10-membered heteroaryl group, or CH2-R5;
R5, in each instance, is one of C6-10aryl, C6-10ar(C1-6)alkyl, C1-6alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group;
where the ring portion of any of said aryl, aralkyl, alkaryl or 5-, 6-, 9- or 10-membered heteroaryl groups of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8) cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl.
R1, at each occurrence, and R2 and R3 are each independently on of hydrogen, C1-8alkyl, C3-10 cycloalkyl, C6-10 aryl, a 5-, 6-, 9- or 10-membered heteroaryl group, or CH2-R5;
R5, in each instance, is one of C6-10aryl, C6-10ar(C1-6)alkyl, C1-6alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group;
where the ring portion of any of said aryl, aralkyl, alkaryl or 5-, 6-, 9- or 10-membered heteroaryl groups of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8) cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl.
76. The compound of claim 67, wherein R3 is C1-12alkyl.
77. The compound of claim 67, wherein R3 is C1-6alkyl.
78. The compound of claim 67, wherein R3 is C4alkyl.
79. The compound of claim 67, wherein R3 is isobutyl.
80. The compound of claim 67, wherein R2 is one of isobutyl, 1-naphthylmethyl, naphthylmethyl, 3-pyridylmethyl, 2-pyridylmethyl, 6-quinolinylmethyl, 3-indolylmethyl, benzyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(2'-pyridylmethoxy)benzyl, 4-(benzyloxy)benzyl, benzylnaphthylmethyl or phenethyl.
81. The compound of claim 67, wherein Z1 and Z2 are independently one of C1-6alkyl, hydroxy, C1-6alkoxy, or C6-10aryloxy.
82. The compound of claim 81, wherein Z1 and Z2 are both hydroxy.
83. The compound of claim 67, wherein together Z1 and Z2 form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.
84. A pharmaceutical composition, comprising a compound of any one of claims 67 to 83, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
85. The pharmaceutical composition according to claim 84, wherein said compound is present in an amount effective to inhibit the proteasome function in a mammal.
86. Use of a compound as claimed in any one of claims 67 to 83 for the manufacture of a medicament for a treatment selected from:
(a) inhibiting the growth of a cancer cell;
(b) reducing the rate of muscle protein degradation;
(c) reducing the activity of NF-.KAPPA.B in a cell;
(d) reducing the activity of intracellular protein breakdown;
(e) reducing the rate of degradation of p53;
(f) inhibiting cyclin degradation in a cell;
(g) preventing or treating an inflammatory condition;
(h) inhibiting antigen presentation in a cell;
(i) inhibiting inducible NF-.KAPPA.B dependent cell adhesion; or (j) inhibiting HIV replication.
(a) inhibiting the growth of a cancer cell;
(b) reducing the rate of muscle protein degradation;
(c) reducing the activity of NF-.KAPPA.B in a cell;
(d) reducing the activity of intracellular protein breakdown;
(e) reducing the rate of degradation of p53;
(f) inhibiting cyclin degradation in a cell;
(g) preventing or treating an inflammatory condition;
(h) inhibiting antigen presentation in a cell;
(i) inhibiting inducible NF-.KAPPA.B dependent cell adhesion; or (j) inhibiting HIV replication.
87. The use according to claim 86, wherein a patient has been diagnosed with, or is at risk of developing a condition selected from the group of tissue rejection, organ rejection, arthritis, an infection, dermatoses, inflammatory bowel disease, asthma, osteoporosis, osteoarthritis, and an autoimmune disease.
88. Use of an effective amount of a compound of any one of claims 1, 7, 14, 21, 32, or 33 to inhibit the growth of a cancer cell.
89. Use of an effective amount of a proteasome inhibitor to reduce the rate of muscle protein degradation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-6alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-6alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
90. Use of an effective amount of a proteasome inhibitor to reduce the activity of NF-.KAPPA.B in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
91. Use of an effective amount of a proteasome inhibitor to reduce the rate of intracellular protein breakdown in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
92. Use of an effective amount of a proteasome inhibitor to reduce the rate of degradation of p53 protein in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)NH--, -CH(OH)-CH2, -CH(OH)-CH(OH), -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)NH--, -CH(OH)-CH2, -CH(OH)-CH(OH), -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
93. ~Use of an effective amount of a proteasome inhibitor to inhibit cyclin degradation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or-CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or-CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
94. Use of an effective amount of a proteasome inhibitor to prevent or treat an inflammatory condition in a patient in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2; -CH(OH)CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2; -CH(OH)CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
95. The use according to claim 94, wherein said patient has been diagnosed with, or is at risk of developing, a condition selected from the group consisting of tissue rejection, organ rejection, arthritis, an infection, dermatoses, inflammatory bowel disease, and an immune disease.
96. Use of an effective amount of a proteasome inhibitor to inhibit antigen presentation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12z is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)CH2-C(O)NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12z is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)CH2-C(O)NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
97. Use of an effective amount of a proteasome inhibitor to inhibit inducible NF-.kappa.B cell adhesion in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-C10)aryl, and halo(C6-C10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-C10)aryl, and halo(C6-C10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
98. Use of an effective amount of a proteasome inhibitor to inhibit HIV
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or-CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-C10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, Cl-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or-CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-C10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, Cl-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 1.
99. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, aryl, alkoxy or aryloxy;
R1 at each occurence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
or a pharmaceutically acceptable salt thereof, wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, aryl, alkoxy or aryloxy;
R1 at each occurence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is naphthylmethyl, pyridylmethyl or quinolinylmethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
100. The compound of claim 99, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R-C(O)-, then R7 can also be saturated or partially saturated heterocycle.
101. The compound of claim 99, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10 aryl, C6-10ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5-to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
102. The compound of claim 99, wherein B1 is CH, and X1 and X2 are each -C(O)-NH-.
103. The compound of claim 99, wherein R1 and R2 are independently selected from the group consisting of alkyl and -CH2-R5, where R5 is one of C6-10 aryl, C1-10 alk(C6-10)aryl, C3-10 cycloalkyl, or a 5-, 6-, 9- or 10-membered heterocycle.
104. The compound of claim 99, wherein R2 is quinolinylmethyl.
105. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-; (CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy and aryloxy;
the R1 that is not adjacent to N-R is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is independently one of aryl, aralkyl, alkaryl, cycloalkyl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or-W-R6, where W is a chalcogen and R6 is alkyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-; (CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R forms together with the adjacent R1, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy and aryloxy;
the R1 that is not adjacent to N-R is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is independently one of aryl, aralkyl, alkaryl, cycloalkyl, a 5- to 10-membered saturated, partially unsaturated or aromatic heterocycle or-W-R6, where W is a chalcogen and R6 is alkyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
106. The compound of claim 105, wherein the nitrogen-containing ring-system is selected from the group consisting of:
107. The compound of claim 105, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O-, then R7 can also be saturated or partially saturated heterocycle.
108. The compound of claim 107, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10aryl, C6-10ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5-to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
109. The compound of claim 105, wherein B1 is CH, and X1 and X2 are each -C(O)-NH-.
110. The compound of claim 105, wherein R1 and R2 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9-or 10- membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
111. The compound of claim 105, wherein P is hydrogen.
112. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1 a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, aryl, alkoxy and aryloxy;
R1 at each occurrence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C610aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is where R9 is one of cycloalkyl, aryl, aralkyl, heteroaryl, heteroaryalkyl, or alkyl which is substituted with one of C1-6 alkyl, halogen, monohalo (C1-6) alkyl, and trifluoromethyl; and wherein said cycloalkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl groups can be optionally substituted with one or two of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
A1 and A2 are independently one of hydrogen, halogen, C1-6 alkyl, monohalo(C1-6)alkyl, or trifluoromethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
or a pharmaceutically acceptable salt thereof;
wherein P is hydrogen or an amino-group-protecting moiety;
B1, at each occurrence, is independently one of N or CH;
X1, at each occurrence, is independently one of -C(O)-NH-,-CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is one of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1 a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, aryl, alkoxy and aryloxy;
R1 at each occurrence, R2 and R3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C610aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, provided that at least one R1, R2 or R3 is where R9 is one of cycloalkyl, aryl, aralkyl, heteroaryl, heteroaryalkyl, or alkyl which is substituted with one of C1-6 alkyl, halogen, monohalo (C1-6) alkyl, and trifluoromethyl; and wherein said cycloalkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl groups can be optionally substituted with one or two of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C6-10 aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
A1 and A2 are independently one of hydrogen, halogen, C1-6 alkyl, monohalo(C1-6)alkyl, or trifluoromethyl;
Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
113. The compound of claim 112, wherein P is R7-C(O)-, R7-SO2-, R7-NH-C(O)- or C(O)-, and R7 is one of alkyl, aryl, alkaryl, aralkyl, heteroaryl or heteroarylalkyl, any of which can be optionally substituted by one ar two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, then R7 can also be saturated or partially saturated heterocycle.
114. The compound of claim 112, wherein P is R7-C(O)- or R7-SO2-; and R7 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, 5- to 10-membered heteroaryl or 5- to 10-membered heteroaryl(C1-6)alkyl, any of which can be optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, alkyl, alkoxy, cyano, C6-10 aryl, benzyl, carboxyalkoxy, amino and guanidino, or when P is R7-C(O)-, R7 can also be N-morpholinyl.
115. The compound of claim 112, wherein X1 and X2 are each -C(O)-NH-.
116. The compound of claim 112, wherein one of R1, R2 or R3 is where A1 and A2 are independently one of hydrogen, C1-6 alkyl, halogen, monohalo (C1-6) alkyl or trifluoromethyl;
R9 is one of C3-10 cycloalkyl, C6-10 aryl, C6-10 ar(C1-6)alkyl, a 5- to 10-membered heteroaryl or a 5- to 10-membered heteroaryl(C1-6)alkyl;
and the remaining R1, R2 and R3 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C6-10)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9 or 10- membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9- or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino.
dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C1-6aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
R9 is one of C3-10 cycloalkyl, C6-10 aryl, C6-10 ar(C1-6)alkyl, a 5- to 10-membered heteroaryl or a 5- to 10-membered heteroaryl(C1-6)alkyl;
and the remaining R1, R2 and R3 are independently selected from the group consisting of alkyl and -CH2-R5, where R5, in each instance, is one of C6-10 aryl, C6-10 ar(C6-10)alkyl, C1-6 alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio or a 5-, 6-, 9 or 10- membered heteroaryl group, where the ring portion of any of said C6-10 aryl, C6-10 ar(C1-6)alkyl, C1-6 alk(C6-10)aryl, or 5-, 6-, 9- or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino.
dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy,hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C1-6aryl, C1-6 alkyl(C6-10)aryl and halo(C6-10)aryl.
117. A pharmaceutical composition, comprising a compound of any one of claims 99, 105 or 112, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
118. A pharmaceutical composition, comprising a compound of claim 102, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
119. A compound of the structure:
or a pharmaceutically acceptable salt thereof; wherein P is R7-C(O)-, R7-NH-C(O)-, R7-O-C(O)-, or R7-SO2-, where R7 is heteroaryl or heteroarylalkyl; or when P is R7-C(O)-, R7 can also be N-morpholinyl;
B1, at each occurrence, is independently one of N or CH;
X1 at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)--CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is selected from the group consisting of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi-, or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aralkyl, alkoxy or aryloxy;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or W-R6, W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
or a pharmaceutically acceptable salt thereof; wherein P is R7-C(O)-, R7-NH-C(O)-, R7-O-C(O)-, or R7-SO2-, where R7 is heteroaryl or heteroarylalkyl; or when P is R7-C(O)-, R7 can also be N-morpholinyl;
B1, at each occurrence, is independently one of N or CH;
X1 at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -CH(OH)--CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-, provided that when B1 is N, then the X1 attached to said B1 is -C(O)-NH-;
X2 is selected from the group consisting of -C(O)-NH-, -CH(OH)-CH2-, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2-, and -CH(OH)-CH2-C(O)-NH-;
R is hydrogen or alkyl, or R forms together with the adjacent R1, a nitrogen-containing mono-, bi-, or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aralkyl, alkoxy or aryloxy;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R2 one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R3 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or W-R6, W is a chalcogen and R6 is alkyl;
where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl, Z1 and Z2 are independently one of alkyl, hydroxy, alkoxy, aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 2.
120. The compound of claim 119, wherein the heteroaryl group in R7 is selected from the group consisting of thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzylfuranyl, benzoxazolyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, .beta.-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl.
121. The compound of claim 119, wherein P is one of quinolinecarbonyl, pyridinecarbonyl, quinolinesulfonyl, quinoxalinecarbonyl, quinoxalinesulfonyl, pyrazinecarbonyl, pyrazinesulfonyl, furancarbonyl, furansulfonyl, or N-morpholinylcarbonyl.
122. The compound of claim 119, wherein P is one of 8-quinolinecarbonyl, 8-quinolinesulfonyl, 2-quinoxalinecarbonyl, 2-quinoxalinesulfonyl, 2-pyrazinecarbonyl, 2-pyrazinesulfonyl, 3-furancarbonyl, 3-furansulfonyl, or N-morpholinylcarbonyl.
123. The compound of claim 119, wherein B1, at each occurrence, is CH.
124. The compound of claim 123, wherein X1, at each occurrence, is -(CO)-NH-.
125. The compound of claim 124, wherein X2 is -(CO)-NH-.
126. The compound of claim 119, wherein R is hydrogen or C1-8 alkyl.
127. The compound of claim 119, wherein:
R1, at each occurrence, and R2 and R3 are each independently on of hydrogen, C1-8alkyl, C3-10 cycloalkyl, C6-10 aryl, a 5-, 6-, 9- or 10-membered heteroaryl group, or CH2-R5;
R5, in each instance, is one of C6-10aryl, C6-10ar(C1-6)alkyl, C1-6alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group;
where the ring portion of any of said aryl, aralkyl, alkaryl or 5-, 6-, 9- or 10-membered heteroaryl groups of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8) cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl.
R1, at each occurrence, and R2 and R3 are each independently on of hydrogen, C1-8alkyl, C3-10 cycloalkyl, C6-10 aryl, a 5-, 6-, 9- or 10-membered heteroaryl group, or CH2-R5;
R5, in each instance, is one of C6-10aryl, C6-10ar(C1-6)alkyl, C1-6alk(C6-10)aryl, C3-10 cycloalkyl, C1-8 alkoxy, C1-8alkylthio or a 5-, 6-, 9- or 10-membered heteroaryl group;
where the ring portion of any of said aryl, aralkyl, alkaryl or 5-, 6-, 9- or 10-membered heteroaryl groups of R1, R2, R3 and R5 can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8) cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl.
128. The compound of claim 119, wherein R3 is C1-12alkyl.
129. The compound of claim 119, wherein R3 is C1-6alkyl.
130. The compound of claim 119, wherein R3 is C4alkyl.
131. The compound of claim 119, wherein R3 is isobutyl.
132. The compound of claim 119, wherein R2 is one of isobutyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyridylmethyl, 2-pyridylmethyl, 6-quinolinylmethyl, 3-indolylmethyl, benzyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(2'-pyridylmethoxy)benzyl, 4-(benzyloxy)benzyl, benzylnaphthylmethyl or phenethyl.
133. The compound of claim 119, wherein Z1 and Z2 are independently one of C1-6alkyl, hydroxy, C1-6alkoxy, or C6-10aryloxy.
134. The compound of claim 133, wherein Z1 and Z2 are both hydroxy.
135. The compound of claim 119, wherein together Z1 and Z2 form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.
136. A pharmaceutical composition, comprising a compound of any one of claims 119 to 135, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
137. The pharmaceutical composition according to claim 136, wherein said compound is present in an amount effective to inhibit the proteasome function in a mammal.
138. Use of a compound as claimed in any one of claims 119 to 135for the manufacture of a medicament for a treatment selected from:
(a) inhibiting the growth of a cancer cell;
(b) reducing the rate of muscle protein degradation;
(c) reducing the activity of NF-.KAPPA.B in a cell;
(d) reducing the activity of intracellular protein breakdown;
(e) reducing the rate of degradation of p53;
(f) inhibiting cyclin degradation in a cell;
(g) preventing or treating an inflammatory condition;
(h) inhibiting antigen presentation in a cell;
(i) inhibiting inducible NF-.KAPPA.B dependent cell adhesion; or (j) inhibiting HIV replication.
(a) inhibiting the growth of a cancer cell;
(b) reducing the rate of muscle protein degradation;
(c) reducing the activity of NF-.KAPPA.B in a cell;
(d) reducing the activity of intracellular protein breakdown;
(e) reducing the rate of degradation of p53;
(f) inhibiting cyclin degradation in a cell;
(g) preventing or treating an inflammatory condition;
(h) inhibiting antigen presentation in a cell;
(i) inhibiting inducible NF-.KAPPA.B dependent cell adhesion; or (j) inhibiting HIV replication.
139. The use according to claim 138, wherein a patient has been diagnosed with, or is at risk of developing a condition selected from the group of tissue rejection, organ rejection, arthritis, an infection, dermatoses, inflammatory bowel disease, asthma, osteoporosis, osteoarthritis, and an autoimmune disease.
140. Use of an effective amount of a compound of any one of claims 99, 105, 112 or 119, to inhibit the growth of a cancer cell.
141. Use of an effective amount of a proteasome inhibitor to reduce the rate of muscle protein degradation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(CH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH), -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulflnyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(CH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH), -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulflnyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
142. Use of an effective amount of a proteasome inhibitor to reduce the activity of NF-.KAPPA.B in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
143. Use of an effective amount of a proteasome inhibitor to reduce the rate of intracellular protein breakdown in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, SO2-CH2- or-CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, SO2-CH2- or-CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
144. Use of an effective amount of a proteasome inhibitor to reduce the rate of degradation of p53 protein in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one; of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy;
hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one; of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy;
hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
145. Use of an effective amount of a proteasome inhibitor to inhibit cyclin degradation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)NH-, provided that when B11 is N, then X11 is -C(O)NH-;
X12 is one of -C(O)-NH-,-CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-1aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10alkyl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6;alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)NH-, provided that when B11 is N, then X11 is -C(O)NH-;
X12 is one of -C(O)-NH-,-CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-1aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10alkyl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6;alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
146. Use of an effective amount of a proteasome inhibitor to prevent or treat an inflammatory condition in a patient in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
147. The use according to claim 146, wherein said patient has been diagnosed with, or is at risk of developing, a condition selected from the group consisting of tissue rejection, organ rejection, arthritis, an infection, dermatoses, inflammatory bowel disease, and an immune disease.
148. Use of an effective amount of a proteasome inhibitor to inhibit antigen presentation in a cell, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl; C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or-CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl; C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
149. Use of an effective amount of a proteasome inhibitor to inhibit inducible NF-kB cell adhesion in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)H(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)H(OH)-, -CH(OH)CH2-NH-, -CH=CH-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
150. Use of an effective amount of a proteasome inhibitor to inhibit HIV
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, --C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or or yloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
replication in an animal in need thereof, wherein said proteasome inhibitor is of the formula:
or a pharmaceutically acceptable salt thereof;
wherein P10 is hydrogen or an amino-group-protecting moiety;
B11 is independently one of N or CH;
X11, at each occurrence, is independently one of -C(O)-NH-, -CH2-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -CH(OH)-CH2-NH-, -CH=CH-, --C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-, provided that when B11 is N, then X11 is -C(O)-NH-;
X12 is one of -C(O)-NH-, -CH(OH)-CH2, -CH(OH)-CH(OH)-, -C(O)-CH2-, -SO2-NH-, -SO2-CH2- or -CH(OH)-CH2-C(O)-NH-;
R10 is hydrogen or alkyl, or R10 forms together with the adjacent R11, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or or yloxy;
R11, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
R12 and R13 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R15, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
where R15 is aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -chalcogen-alkyl, where the ring portion of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted by one or two substituents independently selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8alkenyl, C2-8alkynyl, cyano, amino, C1-6alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6alkoxy, C6-10aryl, C6-10aryl(C1-6)alkyl, C6-10aryl(C1-6)alkoxy, hydroxy, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, C6-10arylthio, C6-10arylsulfinyl, C6-10arylsulfonyl, C6-10aryl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
Z11 and Z12 are independently alkyl, hydroxy, alkoxy, or aryloxy, or together Z11 and Z12 together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O; and A10 is 2.
151. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
wherein Y10 is one of R8-C(O)-, R8-SO2-, R8-NH-C(O)- or R8-O-C(O)-, where R8 is one of alkyl, aryl, alkaryl, aralkyl, any of which can be optionally substituted, or when Y10 is R8-C(O)- or R8-SO2-, then R8 can also be an optionally substituted 5-10 membered, saturated, partially unsaturated or aromatic heterocycle;
X13 is a covalent bond or -C(O)CH2-;
R13 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- 10 membered saturated, partially unsaturated or aromatic heterocycle or CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycleor -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted; and Z11 and Z12 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a moiety derived from dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O;
provided that when Y10 is R8-C(O)-, R8 is other than phenyl, benzyl or C1-3 alkyl.
or a pharmaceutically acceptable salt thereof;
wherein Y10 is one of R8-C(O)-, R8-SO2-, R8-NH-C(O)- or R8-O-C(O)-, where R8 is one of alkyl, aryl, alkaryl, aralkyl, any of which can be optionally substituted, or when Y10 is R8-C(O)- or R8-SO2-, then R8 can also be an optionally substituted 5-10 membered, saturated, partially unsaturated or aromatic heterocycle;
X13 is a covalent bond or -C(O)CH2-;
R13 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5- 10 membered saturated, partially unsaturated or aromatic heterocycle or CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycleor -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted; and Z11 and Z12 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a moiety derived from dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O;
provided that when Y10 is R8-C(O)-, R8 is other than phenyl, benzyl or C1-3 alkyl.
152. The compound of claim 151, wherein P is R8-C(O)- or R8-SO2-; and R8 is one of C6-10 aryl, C6-10 ar(C1-6)alkyl, or a 5-10 membered heteroaryl, any of which can be optionally substituted, or when P is R8-C(O)-, R8 can also be N-morpholinyl.
153. The compound according to claim 151, wherein Y10 is one of where R4 is C6-12 alkyl.
154. A compound having the formula:
or a pharmaceutically acceptable salt thereof;
where Y10 is P is one of R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, where R7 is one of alkyl, aryl, alkaryl, aralkyl, any of which can be optionally substituted, or when Y10 is R7-C(O)- or R1-SO2-, R7 can also be an optionally substituted 5-10 membered saturated, partially unsaturated or aromatic heterocycle;
X13 is a covalent bond or -C(O)-CH2-;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R13 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted; and Z11 and Z12 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a moiety derived from dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O.
or a pharmaceutically acceptable salt thereof;
where Y10 is P is one of R7-C(O)-, R7-SO2-, R7-NH-C(O)- or R7-O-C(O)-, where R7 is one of alkyl, aryl, alkaryl, aralkyl, any of which can be optionally substituted, or when Y10 is R7-C(O)- or R1-SO2-, R7 can also be an optionally substituted 5-10 membered saturated, partially unsaturated or aromatic heterocycle;
X13 is a covalent bond or -C(O)-CH2-;
R1, at each occurrence, is independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R13 is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or CH2-R5, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;
R5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or -W-R6, where W is a chalcogen and R6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted; and Z11 and Z12 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a moiety derived from dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O.
155. The compound of claim 154, wherein Y10 is:
156. A pharmaceutical composition, comprising a compound of claim 151 or 154, or a pharmaceutically acceptable salt thereof, arid a pharmaceutically-acceptable carrier or diluent.
157. A pharmaceutical composition, comprising a compound of claim 153 or 155, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
158. Use of an effective amount of a compound of claim 151 or 154 to reduce the rate of muscle protein degradation in a cell.
159. Use of an effective amount of a compound of claim 151 or 154 to reduce the activity of NF-.KAPPA.B in a cell.
160. Use of an effective amount of a compound of claim 151 or 154 to reduce the rate of intracellular protein breakdown in a cell.
161. Use of an effective amount of a compound of claim 151 or 154 to reduce the rate of degradation of p53 protein in. a cell.
162. Use of an effective amount of a compound of claim 151 or 154 to inhibit cyclin degradation in a cell.
163. Use of an effective amount of a compound of claim 151 or 154 to prevent or treat an inflammatory condition in a patient in need thereof.
164. The use according to claim 163, wherein said patient has been diagnosed with, or is at risk of developing, a condition selected from the group consisting of tissue rejection, organ rejection, arthritis, an infection, dermatoses, inflammatory bowel disease, and an immune disease.
165. Use of an effective amount of a compound of claim 151 or 154 to inhibit the growth of a cancer cell.
166. Use of an effective amount of a compound of claim 151 or 154 to inhibit antigen presentation in a cell.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33052594A | 1994-10-28 | 1994-10-28 | |
US08/330,525 | 1994-10-28 | ||
US08/442,581 US6083903A (en) | 1994-10-28 | 1995-05-16 | Boronic ester and acid compounds, synthesis and uses |
US08/442,581 | 1995-05-16 | ||
CA002203936A CA2203936C (en) | 1994-10-28 | 1995-10-27 | Boronic ester and acid compounds, synthesis and uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002203936A Division CA2203936C (en) | 1994-10-28 | 1995-10-27 | Boronic ester and acid compounds, synthesis and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2496538A1 true CA2496538A1 (en) | 1996-05-09 |
CA2496538C CA2496538C (en) | 2011-08-02 |
Family
ID=26987313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2496538A Expired - Lifetime CA2496538C (en) | 1994-10-28 | 1995-10-27 | Boronic ester and acid compounds, synthesis and uses |
CA002203936A Expired - Lifetime CA2203936C (en) | 1994-10-28 | 1995-10-27 | Boronic ester and acid compounds, synthesis and uses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002203936A Expired - Lifetime CA2203936C (en) | 1994-10-28 | 1995-10-27 | Boronic ester and acid compounds, synthesis and uses |
Country Status (25)
Country | Link |
---|---|
US (16) | US6083903A (en) |
EP (4) | EP1312609B1 (en) |
JP (1) | JP3717934B2 (en) |
KR (1) | KR100398944B1 (en) |
CN (2) | CN101077875B (en) |
AT (3) | ATE241631T1 (en) |
AU (1) | AU710564B2 (en) |
CA (2) | CA2496538C (en) |
CH (1) | CH0788360H1 (en) |
CY (1) | CY2484B1 (en) |
DE (5) | DE69530936T3 (en) |
DK (3) | DK1627880T3 (en) |
ES (3) | ES2314540T3 (en) |
FI (2) | FI114801B (en) |
FR (1) | FR04C0014I2 (en) |
HK (2) | HK1002059A1 (en) |
IL (5) | IL115790A (en) |
LU (1) | LU91083I2 (en) |
MX (1) | MX9703063A (en) |
NL (1) | NL300151I2 (en) |
NO (2) | NO310558B1 (en) |
NZ (2) | NZ296717A (en) |
PT (3) | PT1627880E (en) |
TW (1) | TW318850B (en) |
WO (1) | WO1996013266A1 (en) |
Families Citing this family (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6838477B2 (en) * | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
FR2758329B1 (en) * | 1997-01-16 | 1999-02-12 | Synthelabo | BORONIC IMIDAZOLE-4-BUTANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
AU741802B2 (en) | 1997-02-15 | 2001-12-13 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of NF-kappaB |
US6221888B1 (en) * | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
EP1017398A1 (en) * | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
KR100458403B1 (en) * | 1997-09-29 | 2004-11-26 | 포인트 써러퓨틱스, 인크. | Stimulation of Hematopoietic Cells in vitro |
US6831057B2 (en) * | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
CA2219867A1 (en) * | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
DE19802450A1 (en) * | 1998-01-23 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | New saccharide compounds useful in treating schizophrenia |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
FR2779653B1 (en) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | USE OF PROTEASOME MODULATING COMPOUNDS IN THERAPY |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
EP0982317A1 (en) * | 1998-08-26 | 2000-03-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
EP1123412B1 (en) * | 1998-10-20 | 2004-10-06 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US6649593B1 (en) * | 1999-10-13 | 2003-11-18 | Tularik Inc. | Modulators of SREBP processing |
CA2419238A1 (en) * | 2000-08-16 | 2002-02-21 | University Of Alberta | Non-pressurized methods for the preparation of conjugated solid supports for boronic acids |
US6919382B2 (en) | 2000-08-31 | 2005-07-19 | The Governors Of The University Of Alberta | Preparation and uses of conjugated solid supports for boronic acids |
EP1430903A1 (en) * | 2000-10-12 | 2004-06-23 | Viromics Gmbh | Use of proteasome inhibitors for the treatment of viral infections |
TR201819416T4 (en) * | 2001-01-25 | 2019-01-21 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Formulation of boronic acid compounds. |
US7112588B2 (en) * | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
PL367287A1 (en) | 2001-05-21 | 2005-02-21 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
EP1399468B1 (en) | 2001-05-30 | 2006-02-15 | Novartis AG | 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
WO2003033507A1 (en) * | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same |
WO2003033506A1 (en) * | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Aminoborane acid derivative and proteasome inhibitory drug containing the same |
US7524883B2 (en) | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
EP1487459A4 (en) * | 2002-03-12 | 2006-05-24 | Ariad Pharma Inc | Peptide analogues and uses thereof |
KR20040093692A (en) * | 2002-03-13 | 2004-11-08 | 얀센 파마슈티카 엔.브이. | Piperazinyl-, piperidynyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
US7501417B2 (en) | 2002-03-13 | 2009-03-10 | Janssen Pharmaceutica, N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
CN100503599C (en) * | 2002-03-13 | 2009-06-24 | 詹森药业有限公司 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
JP4725945B2 (en) | 2002-03-13 | 2011-07-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Sulfonylamino derivatives as novel inhibitors of histone deacetylase |
ATE481104T1 (en) * | 2002-04-05 | 2010-10-15 | Virologik Gmbh | AGENTS FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS |
US7514579B2 (en) * | 2002-06-13 | 2009-04-07 | Johns Hopkins University | Boronic chalcone derivatives and uses thereof |
JP2006506442A (en) * | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス, インコーポレイテッド | Boroproline compound combination therapy |
WO2004016253A1 (en) * | 2002-08-14 | 2004-02-26 | Janssen Pharmaceutica N.V. | Use of nf-kappa b inhibitors for the treatment of mastitis |
US20050282757A1 (en) * | 2002-09-09 | 2005-12-22 | Trigen Limited | Peptide boronic acid compounds useful in anticoagulation |
US20050119226A1 (en) * | 2003-09-09 | 2005-06-02 | Trigen Limited | Methods for synthesizing organoboronic compounds and products thereof |
US7112572B2 (en) * | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
WO2004022071A1 (en) * | 2002-09-09 | 2004-03-18 | Trigen Limited | Multivalent metal salts of boronic acids for treating thrombosis |
US20050176651A1 (en) * | 2002-09-09 | 2005-08-11 | Trigen Limited | Peptide boronic acids useful in making salts thereof |
WO2004026406A1 (en) * | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
CA2508348C (en) | 2002-12-06 | 2016-07-12 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
CN100341880C (en) * | 2003-02-13 | 2007-10-10 | 上海仁虎制药股份有限公司 | Boric acid and boric acid ester compound ,their preparing method and use in pharmacy |
US20070110785A1 (en) * | 2003-07-03 | 2007-05-17 | Eugene Tedeschi | Medical devices with proteasome inhibitors for the treatment of restenosis |
US7223745B2 (en) * | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
JP2007513072A (en) | 2003-11-05 | 2007-05-24 | パリンゲン インコーポレーテッド | Enhanced B cell cytotoxicity in CDIM binding antibodies |
US20060052390A1 (en) * | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
BRPI0507972A (en) * | 2004-02-23 | 2007-07-24 | Tufts College | compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition |
GB0405272D0 (en) * | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
US7371875B2 (en) * | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
AU2016202747B2 (en) * | 2004-03-30 | 2017-11-23 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
UA90108C2 (en) | 2004-03-30 | 2010-04-12 | Мілленніум Фармасьютікалз, Інк. | Synthesis of boronic ester and acid compounds |
WO2005105827A2 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
BRPI0510802A (en) | 2004-05-10 | 2007-11-06 | Proteolix Inc | enzyme inhibiting compounds |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
ATE553077T1 (en) | 2004-07-23 | 2012-04-15 | Nuada Llc | PEPTIDATE INHIBITORS |
JP4948403B2 (en) | 2004-07-28 | 2012-06-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Substituted indolylalkylamino derivatives as new inhibitors of histone deacetylase |
WO2006045066A2 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
US8377435B2 (en) | 2004-11-05 | 2013-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody induced cell membrane wounding |
TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
US20090018146A1 (en) * | 2005-01-27 | 2009-01-15 | Research Development Corporation | Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors |
US7468383B2 (en) * | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
PT1853251E (en) | 2005-02-16 | 2013-07-19 | Anacor Pharmaceuticals Inc | Halogen-substituted boronophthalides for the treatment of infections |
WO2006099261A2 (en) * | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
KR20080007642A (en) * | 2005-04-29 | 2008-01-22 | 코산 바이오사이언시즈, 인코포레이티드 | Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor |
EP1885710B1 (en) | 2005-05-18 | 2015-08-19 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
WO2006133052A2 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
WO2007002972A2 (en) * | 2005-07-06 | 2007-01-11 | Biodevelops Pharma Entwicklung Gmbh | Use of a compound for enhancing the expression of membrane proteins on the cell surface |
EP1752467A1 (en) | 2005-08-10 | 2007-02-14 | 4Sc Ag | Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
US7531517B2 (en) | 2005-08-10 | 2009-05-12 | 4Sc Ag | Inhibitors of cancer cell, T-cell and keratinocyte proliferation |
US20070059382A1 (en) * | 2005-09-09 | 2007-03-15 | Board Of Regents, Univ. And Comm. College System Of Nevada... | Medical treatment of breast cancer with boric acid materials |
JP5436860B2 (en) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス, インク. | Compounds for enzyme inhibition |
EP1956908A2 (en) * | 2005-12-08 | 2008-08-20 | Cytokinetics, Inc. | Certain compositions and methods of treatment |
CN105949230A (en) | 2005-12-30 | 2016-09-21 | 安纳考尔医药公司 | Boron-containing small molecules |
EP1979327A1 (en) * | 2006-01-19 | 2008-10-15 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
WO2007082882A1 (en) * | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
SI1981874T1 (en) * | 2006-01-19 | 2009-10-31 | Janssen Pharmaceutica Nv | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
ES2396986T3 (en) | 2006-01-19 | 2013-03-01 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as histone deacetylase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
PE20070978A1 (en) * | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
SI2719388T1 (en) | 2006-02-16 | 2019-06-28 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
DE102006026464A1 (en) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmaceutical composition for the treatment of viral infections and / or tumors by inhibiting protein folding and protein degradation |
WO2007143600A2 (en) * | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
US7691852B2 (en) | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
AU2007296259A1 (en) * | 2006-09-15 | 2008-03-20 | Janssen Pharmaceutica Nv | Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
EA020276B1 (en) * | 2006-09-15 | 2014-10-30 | Янссен Фармацевтика Нв | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
AU2007221966A1 (en) * | 2006-12-08 | 2008-06-26 | Centenary Institute Of Cancer Medicine And Cell Biology | Assay for response to proteasome inhibitors |
JO3396B1 (en) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
DK2185693T3 (en) | 2007-07-31 | 2019-09-23 | Lifescan Inc | DIFFERENTIZING HUMAN EMBRYONIC STEM CELLS |
SI2170396T1 (en) | 2007-08-03 | 2017-04-26 | Summit (Oxford) Limited | Drug combinations for the treatment of duchenne muscular dystrophy |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
AU2016253697A1 (en) * | 2007-08-06 | 2016-11-24 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
CN101772507B (en) * | 2007-08-06 | 2012-12-12 | 米伦纽姆医药公司 | Proteasome inhibitors |
EA034601B1 (en) * | 2007-08-06 | 2020-02-25 | Милленниум Фармасьютикалз, Инк. | Process for producing boronic acids |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
US20100226597A1 (en) * | 2007-09-12 | 2010-09-09 | Dr. Reddy's Laboratories Limited | Bortezomib and process for producing same |
US20090076031A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched bortezomib |
MY173938A (en) | 2007-10-04 | 2020-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
US7838673B2 (en) * | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US20090110688A1 (en) * | 2007-10-24 | 2009-04-30 | Georg Fertig | Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
CN107574142B (en) * | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | Differentiation of human embryonic stem cells |
CN101220048B (en) * | 2007-12-14 | 2012-08-15 | 江苏先声药物研究有限公司 | Method for preparing pinane diol ester under ZnCl2 catalysis |
UY31545A1 (en) | 2007-12-20 | 2009-08-03 | NEW DERIVATIVES OF 2-CARBOXAMIDE CIANOAMINOUREA, ITS SALTS AND PHARMACEUTICALLY ACCEPTABLE PROFARMS, PREPARATION PROCESSES AND APPLICATIONS | |
CA2715878C (en) | 2008-02-21 | 2017-06-13 | Centocor Ortho Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
KR101672511B1 (en) * | 2008-03-06 | 2016-11-03 | 아나코르 파마슈티칼스 인코포레이티드 | Boron-containing small molecules as anti-inflammatory agents |
WO2009140309A2 (en) * | 2008-05-12 | 2009-11-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
EA027346B1 (en) * | 2008-06-17 | 2017-07-31 | Милленниум Фармасьютикалз, Инк. | Boronate ester compounds and pharmaceutical compositions thereof |
KR20180018839A (en) | 2008-06-30 | 2018-02-21 | 얀센 바이오테크 인코포레이티드 | Differentiation of pluripotent stem cells |
CN101638414B (en) * | 2008-07-30 | 2014-01-08 | 江苏先声药物研究有限公司 | Peptidyl boronic acid, ester compound thereof, preparation method of peptidyl boronic acid and ester compound thereof, and use of peptidyl boronic acid and ester compound thereof |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
EP2348863A4 (en) * | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
AR075090A1 (en) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
US9493489B2 (en) * | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
KR20110073584A (en) | 2008-10-21 | 2011-06-29 | 오닉스 세라퓨틱스, 인크. | Combination therapy with peptide epoxyketones |
JP2012507289A (en) * | 2008-10-31 | 2012-03-29 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells into the pancreatic endocrine system |
US9234178B2 (en) | 2008-10-31 | 2016-01-12 | Janssen Biotech, Inc. | Differentiation of human pluripotent stem cells |
EP2366022B1 (en) * | 2008-11-20 | 2016-04-27 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
MX356756B (en) | 2008-11-20 | 2018-06-11 | Centocor Ortho Biotech Inc | Pluripotent stem cell culture on micro-carriers. |
CN101747354B (en) * | 2008-12-04 | 2014-08-13 | 江苏先声药物研究有限公司 | Dipeptide boronic acids consisting of beta amino acids, ester compounds and preparation methods and uses thereof |
KR20110111407A (en) * | 2008-12-17 | 2011-10-11 | 아나코르 파마슈티칼스 인코포레이티드 | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol |
CA2748921A1 (en) * | 2009-01-09 | 2010-08-12 | Sun Pharma Advanced Research Company Limited | Bortezumib containing pharmaceutical composition |
EP3021120A1 (en) | 2009-02-20 | 2016-05-18 | Michael P. Lisanti | Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample |
US8536161B2 (en) | 2009-03-12 | 2013-09-17 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
WO2010106135A1 (en) | 2009-03-20 | 2010-09-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combined use for the treatment of ovarian carcinoma |
AR075899A1 (en) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | PROTEASA INHIBITING CRYSTALLINE EPOXYCETON TRIPEPTIDES |
WO2010111361A1 (en) * | 2009-03-24 | 2010-09-30 | Janssen Pharmaceutica Nv | Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor |
WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
MX2011012538A (en) * | 2009-05-27 | 2012-02-08 | Cephalon Inc | Combination therapy for the treatment of multiple myeloma. |
CA2765811C (en) | 2009-06-19 | 2018-06-05 | Lek Pharmaceuticals D.D. | Process for hydrogenation of halogenoalkenes without dehalogenation |
EP2270019A1 (en) | 2009-06-19 | 2011-01-05 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters |
EP2280016A1 (en) | 2009-07-27 | 2011-02-02 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes |
CN101928329B (en) * | 2009-06-19 | 2013-07-17 | 北京大学 | Tripeptide boric acid (ester) compound and preparation method and application thereof |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
DE102009027754A1 (en) | 2009-07-15 | 2011-05-05 | Schubert, Ulrich, Dr. | Method for inhibiting the maturation of dendritic cells |
JP6219568B2 (en) | 2009-07-20 | 2017-10-25 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells |
US8785185B2 (en) | 2009-07-20 | 2014-07-22 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
JP5819825B2 (en) * | 2009-07-20 | 2015-11-24 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells |
US8343944B2 (en) * | 2009-07-28 | 2013-01-01 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
WO2011019618A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011022502A1 (en) | 2009-08-18 | 2011-02-24 | Georgetown University | Boronic acid compositions and methods related to cancer |
US20110207701A1 (en) * | 2009-08-19 | 2011-08-25 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
JP5567136B2 (en) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4-Substituted pyridin-3-yl-carboxamide compounds and methods of use |
US20110124597A1 (en) * | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
DK2519231T3 (en) * | 2009-10-01 | 2017-06-26 | Janssen Pharmaceutica Nv | Proteasome inhibitors for the treatment of cancer |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US20110212918A1 (en) * | 2009-11-11 | 2011-09-01 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
EP2516449A1 (en) | 2009-12-22 | 2012-10-31 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
RU2664864C1 (en) | 2009-12-23 | 2018-08-23 | Янссен Байотек, Инк. | Ways to increase expression of ngn3 and nkx6.1 in pancreatic endocrine cells |
MX343786B (en) | 2009-12-23 | 2016-11-22 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US8716478B2 (en) | 2010-01-27 | 2014-05-06 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
JP6013196B2 (en) * | 2010-03-01 | 2016-10-25 | ヤンセン バイオテツク,インコーポレーテツド | Method for purifying cells derived from pluripotent stem cells |
EP2542238B1 (en) * | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
EP2547333B1 (en) * | 2010-03-18 | 2017-08-23 | Innopharma, Inc. | Stable bortezomib formulations |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
AP2012006482A0 (en) | 2010-03-19 | 2012-10-31 | Anacor Pharmacueticals Inc | Boron-containing small molecules as anti-protozoalagent |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
EA029521B1 (en) | 2010-03-31 | 2018-04-30 | Милленниум Фармасьютикалз, Инк. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
AU2013204868B2 (en) * | 2010-03-31 | 2016-10-13 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
MX2012011604A (en) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor. |
CN101812026B (en) * | 2010-04-12 | 2013-08-28 | 亚邦医药股份有限公司 | Method for synthesizing bortezomib |
EP2560647B1 (en) | 2010-04-19 | 2016-04-13 | Niiki Pharma Inc. | Combination therapy with a proteasome inhibitor and a gallium complex |
WO2011139379A2 (en) | 2010-05-06 | 2011-11-10 | Duke University | A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
RU2587634C2 (en) | 2010-05-12 | 2016-06-20 | Янссен Байотек, Инк. | Differentiation of human embryo stem cells |
EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treatment of autoimmune and other diseases |
AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
ES2585028T3 (en) | 2010-08-31 | 2016-10-03 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
KR101851956B1 (en) | 2010-08-31 | 2018-04-25 | 얀센 바이오테크 인코포레이티드 | Differentiation of human embryonic stem cells |
ES2659393T3 (en) | 2010-08-31 | 2018-03-15 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
BR112013005426B1 (en) | 2010-09-07 | 2021-08-24 | Anacor Pharmaceuticals, Inc | COMPOUND, COMPOSITION, COMBINATION, AND, PHARMACEUTICAL FORMULATION |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
CA2813003A1 (en) | 2010-10-05 | 2012-04-12 | Fresenius Kabi Usa, Llc | Bortezomib formulations stabilised with boric acid |
ES2548256T3 (en) | 2010-10-14 | 2015-10-15 | Synthon Bv | Process for the preparation of bortezomib and intermediates for the process |
PT2670753T (en) | 2011-01-31 | 2017-01-10 | Novartis Ag | Novel heterocyclic derivatives |
TW201309303A (en) * | 2011-03-03 | 2013-03-01 | Cephalon Inc | Proteasome inhibitor for the treatment of lupus |
WO2012135528A2 (en) | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
WO2012133884A1 (en) | 2011-03-31 | 2012-10-04 | ナノキャリア株式会社 | Pharmaceutical composition containing block copolymer comprising boric acid compound |
EP2691530B1 (en) | 2011-06-10 | 2018-03-07 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US20140121182A1 (en) * | 2011-06-22 | 2014-05-01 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
US8481655B2 (en) | 2011-07-27 | 2013-07-09 | Wacker Chemical Corporation | Copper complexes of amino-functional organosilicon compounds and their use |
WO2013021032A1 (en) | 2011-08-11 | 2013-02-14 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone |
ES2586328T3 (en) | 2011-08-11 | 2016-10-13 | Janssen Pharmaceutica, N.V. | Predisposing factors for cancer treatment |
CA2844086A1 (en) | 2011-08-19 | 2013-02-28 | Glaxo Group Limited | Benzofuran compounds for the treatment of hepatitis c virus infections |
CN108383893A (en) * | 2011-08-30 | 2018-08-10 | 塔夫茨大学信托人 | The proteasome inhibitor that FAP- for treating solid tumor is activated |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2776144T3 (en) | 2011-10-28 | 2020-07-29 | Millennium Pharm Inc | Biomarkers of response to NAE inhibitors |
EP2771342B1 (en) | 2011-10-28 | 2016-05-18 | Novartis AG | Purine derivatives and their use in the treatment of disease |
CA2855368A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CN104039328B (en) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | To the biomarker of the reaction of proteasome inhibitor |
KR101912978B1 (en) | 2011-11-17 | 2018-10-29 | 도꾜 다이가꾸 | Block copolymer having phenylboronic acid group introduced therein, and use thereof |
RU2705001C2 (en) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Differentiation of human embryonic stem cells into single-hormonal insulin-positive cells |
WO2013110005A1 (en) | 2012-01-18 | 2013-07-25 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
US9732101B2 (en) | 2012-01-18 | 2017-08-15 | Wisconsin Alumni Research Foundation | Bioreversible boronates for delivery of molecules into cells |
WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
MX363819B (en) | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Cdim binding proteins and uses thereof. |
US10293048B2 (en) | 2012-03-02 | 2019-05-21 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
CA2866590A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
JP6469003B2 (en) | 2012-06-08 | 2019-02-13 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
EP2869820A4 (en) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | Prodrugs of peptide epoxy ketone protease inhibitors |
JP2013006855A (en) * | 2012-09-03 | 2013-01-10 | Millennium Pharmaceuticals Inc | Proteasome inhibitor |
BR112015005343A2 (en) * | 2012-09-11 | 2017-07-04 | Cipla Ltd | process for the preparation of bortezomib, compound, bortezomib or its anhydride, and process for the preparation of a compound |
CA2886783A1 (en) | 2012-10-01 | 2014-04-10 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
WO2014072985A1 (en) | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
EP2919786A4 (en) | 2012-11-16 | 2016-06-01 | Shilpa Medicare Ltd | Crystalline bortezomib process |
WO2014097306A1 (en) | 2012-12-21 | 2014-06-26 | Natco Pharma Limited | Stable and pure polymorphic form of bortezomib |
EP2938723B1 (en) | 2012-12-31 | 2023-02-01 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
JP6557146B2 (en) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク,インコーポレーテツド | Culture of human embryonic stem cells at the air-liquid interface for differentiation from pluripotent stem cells to pancreatic endocrine cells |
EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
KR102194745B1 (en) | 2013-03-13 | 2020-12-24 | 포르마 세라퓨틱스 인크. | Novel compounds and compositions for inhibition of fasn |
US10023611B2 (en) | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US10478445B2 (en) | 2013-07-03 | 2019-11-19 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
KR20160058886A (en) | 2013-10-03 | 2016-05-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN104586776B (en) * | 2013-10-30 | 2017-05-17 | 扬子江药业集团上海海尼药业有限公司 | Preparation taking bortezomib as active composition and preparation method thereof |
WO2015076359A1 (en) * | 2013-11-21 | 2015-05-28 | 国立大学法人北海道大学 | Proteasome-inhibiting compound |
WO2015085097A1 (en) * | 2013-12-05 | 2015-06-11 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
PT3076969T (en) | 2013-12-06 | 2021-11-23 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
US10167311B2 (en) | 2014-02-03 | 2019-01-01 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
EP2910557A1 (en) * | 2014-02-20 | 2015-08-26 | Ikerchem, S.L. | Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof |
US10993960B1 (en) | 2014-05-08 | 2021-05-04 | Kawasaki Institute Of Industrial Promotion | Pharmaceutical composition |
CA2949056A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
UY36132A (en) | 2014-05-20 | 2015-11-30 | Millennium Pharm Inc | METHODS FOR CANCER THERAPY |
EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
CN107074885B (en) * | 2014-10-01 | 2020-11-27 | 默克专利股份公司 | Boronic acid derivatives |
WO2016110870A1 (en) | 2015-01-07 | 2016-07-14 | Emcure Pharmaceuticals Limited | Pharmaceutical composition of bortezomid |
MA41505A (en) | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | NEW CRYSTALLINE FORM OF A PROTEASOME INHIBITOR |
US20180243217A1 (en) | 2015-03-17 | 2018-08-30 | Leon-Nanodrugs Gmbh | Nanoparticles comprising a stabilized boronic acid compound |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2016184793A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma |
WO2016205790A2 (en) | 2015-06-19 | 2016-12-22 | Hanlin Scientific, Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
EP3120837A1 (en) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Ready-to-use solution of bortezomib |
CN106478700B (en) * | 2015-08-26 | 2020-12-29 | 杭州雷索药业有限公司 | Boron-substituted aniline protein kinase inhibitor |
CN106588965A (en) * | 2015-10-15 | 2017-04-26 | 北京大学 | Urea peptidomimetic boric acid compound as well as pharmaceutical composition, preparation method and application thereof |
MX2018005298A (en) | 2015-11-02 | 2018-06-22 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. |
EP3389715A4 (en) | 2015-12-14 | 2019-06-12 | David K. Thomas | Compositions and methods for treating cardiac dysfunction |
CN107151254A (en) * | 2016-03-06 | 2017-09-12 | 复旦大学 | It is a kind of to be used as boric acid compound of 20S proteasome inhibitors and preparation method thereof |
CN107151255A (en) * | 2016-03-06 | 2017-09-12 | 复旦大学 | Boric acid compound and its production and use |
MA45479A (en) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
CN106008572B (en) * | 2016-05-23 | 2018-08-17 | 成都千禧莱医药科技有限公司 | A kind of dipeptide boronic acid compound and preparation method and purposes |
EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
KR102595723B1 (en) | 2016-06-21 | 2023-10-27 | 오리온 옵탈몰로지 엘엘씨 | Heterocyclic Prolinamide Derivatives |
JP6681284B2 (en) * | 2016-06-23 | 2020-04-15 | 信越化学工業株式会社 | Method for reducing metal of sugar alcohol compound |
JP6223508B2 (en) * | 2016-06-27 | 2017-11-01 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Proteasome inhibitor |
WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
WO2018073790A1 (en) | 2016-10-20 | 2018-04-26 | Pfizer Inc. | Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same |
ES2914123T3 (en) | 2017-01-09 | 2022-06-07 | Shuttle Pharmaceuticals Inc | Selective histone deacetylase inhibitors for the treatment of a human disease |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CN110312727A (en) | 2017-02-17 | 2019-10-08 | 费森尤斯卡比肿瘤学有限公司 | A kind of improved method for preparing borate |
EP3589659A4 (en) | 2017-02-28 | 2021-03-24 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
CN117338932A (en) | 2017-08-23 | 2024-01-05 | 科智生命科学公司 | Immunoproteasome inhibitors and immunosuppressives in the treatment of autoimmune disorders |
WO2019053611A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
JP2018024694A (en) * | 2017-10-03 | 2018-02-15 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Proteasome inhibitor |
ES2928787T3 (en) * | 2017-11-16 | 2022-11-22 | Principia Biopharma Inc | Immunoproteasome inhibitors |
IL274523B2 (en) | 2017-11-16 | 2024-02-01 | Principia Biopharma Inc | Immunoproteasome inhibitors |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
CA3087565A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
CN109824756B (en) * | 2019-03-19 | 2022-03-22 | 山东大学 | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof |
CN114437119A (en) * | 2020-10-30 | 2022-05-06 | 苏州开拓药业股份有限公司 | C-Myc protein inhibitor and preparation method and application thereof |
US20240016815A1 (en) * | 2020-12-02 | 2024-01-18 | Hoffman Technologies Llc | Compositions and methods for modulating cancer in non-human mammals |
TW202237143A (en) * | 2020-12-10 | 2022-10-01 | 南韓商Lg化學股份有限公司 | Boronic acid compounds |
US20230062279A1 (en) | 2021-08-12 | 2023-03-02 | Extrovis Ag | Pharmaceutical compositions of bortezomib |
CN113957441B (en) * | 2021-10-29 | 2024-01-02 | 光华科学技术研究院(广东)有限公司 | Etching solution and preparation method and application thereof |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261868A (en) * | 1979-08-08 | 1981-04-14 | Lever Brothers Company | Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound |
US4369183A (en) * | 1979-09-06 | 1983-01-18 | Merck & Co., Inc. | 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors |
US4510130A (en) | 1983-05-20 | 1985-04-09 | Genetic Diagnostics Corporation | Promoting animal and plant growth with leupeptin |
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US4537707A (en) * | 1984-05-14 | 1985-08-27 | The Procter & Gamble Company | Liquid detergents containing boric acid and formate to stabilize enzymes |
US4842769A (en) * | 1985-07-26 | 1989-06-27 | Colgate-Palmolive Co. | Stabilized fabric softening built detergent composition containing enzymes |
US4759032A (en) | 1987-06-03 | 1988-07-19 | Monsanto Company | Electrode seal assembly |
US5187157A (en) * | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5242904A (en) * | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
SE8702550D0 (en) * | 1987-06-18 | 1987-06-18 | Anders Grubb | CYSTEINPROTEASHEMMARE |
KR960012512B1 (en) | 1987-06-19 | 1996-09-20 | 캔디스 엘. 볼커 | A new class of low calorie protein sweeteners |
EP0315574A3 (en) * | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin inhibitors |
US5106948A (en) * | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US4963655A (en) * | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
DE3827340A1 (en) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | USE OF (ALPHA) -AMINOBORONIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF VIRUS DISEASES |
ZA897515B (en) * | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
US4997929A (en) * | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
US4959179A (en) * | 1989-01-30 | 1990-09-25 | Lever Brothers Company | Stabilized enzymes liquid detergent composition containing lipase and protease |
JP2701932B2 (en) * | 1989-04-10 | 1998-01-21 | サントリー株式会社 | Protease inhibitor |
US5030378A (en) * | 1990-01-02 | 1991-07-09 | The Procter & Gamble Company | Liquid detergents containing anionic surfactant, builder and proteolytic enzyme |
AU661270B2 (en) | 1990-03-05 | 1995-07-20 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
EP0478050A1 (en) * | 1990-09-24 | 1992-04-01 | Unilever N.V. | Detergent composition |
GB9024129D0 (en) * | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
JP2703408B2 (en) | 1990-12-28 | 1998-01-26 | 麒麟麦酒株式会社 | 1,4-benzothiazepine derivatives |
JPH06504061A (en) * | 1990-12-28 | 1994-05-12 | コーテックス ファーマシューティカルズ インコーポレイテッド | Use of calpain inhibitors in the treatment and prevention of neurodegeneration |
EP0564561A4 (en) * | 1990-12-28 | 1994-08-10 | Georgia Tech Res Inst | Peptides ketoamides, ketoacids, and ketoesters |
AU666660B2 (en) * | 1991-04-30 | 1996-02-22 | Procter & Gamble Company, The | Built liquid detergents with boric-polyol complex to inhibit proteolytic enzyme |
EP0511456A1 (en) * | 1991-04-30 | 1992-11-04 | The Procter & Gamble Company | Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme |
JPH06507198A (en) * | 1991-04-30 | 1994-08-11 | ザ、プロクター、エンド、ギャンブル、カンパニー | Liquid cleaning agents containing arylboronic acids |
US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
AU4077193A (en) * | 1992-04-16 | 1993-11-18 | Zeneca Limited | Alpha-aminoboronic acid peptides and their use as elastase inhibitors |
DE69314169T2 (en) * | 1992-04-16 | 1998-01-15 | Zeneca Ltd | PEPTIDES WITH AN ALPHAAMINOBORONAIRE GROUP AND THEIR USE AS AN ELASTASE INHIBITOR |
EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
WO1994017816A1 (en) | 1993-02-10 | 1994-08-18 | The President And Fellows Of Harvard College | Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof |
US5384410A (en) * | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
DE4311835A1 (en) * | 1993-04-07 | 1994-10-13 | Boehringer Ingelheim Int | Method for inhibiting gene transcription |
US5424904A (en) | 1993-10-04 | 1995-06-13 | Taylor, Sr.; Thomas T. | Circuit for electrically controlled intermittent motion |
IL111176A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them |
US5693617A (en) * | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) * | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5550262A (en) * | 1994-11-14 | 1996-08-27 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
TR201819416T4 (en) * | 2001-01-25 | 2019-01-21 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Formulation of boronic acid compounds. |
UA90108C2 (en) * | 2004-03-30 | 2010-04-12 | Мілленніум Фармасьютікалз, Інк. | Synthesis of boronic ester and acid compounds |
-
1995
- 1995-05-16 US US08/442,581 patent/US6083903A/en not_active Expired - Lifetime
- 1995-10-27 TW TW084111436A patent/TW318850B/zh not_active IP Right Cessation
- 1995-10-27 WO PCT/US1995/014117 patent/WO1996013266A1/en active IP Right Grant
- 1995-10-27 CA CA2496538A patent/CA2496538C/en not_active Expired - Lifetime
- 1995-10-27 PT PT05023462T patent/PT1627880E/en unknown
- 1995-10-27 DE DE69530936T patent/DE69530936T3/en not_active Expired - Lifetime
- 1995-10-27 DK DK05023462T patent/DK1627880T3/en active
- 1995-10-27 ES ES05023462T patent/ES2314540T3/en not_active Expired - Lifetime
- 1995-10-27 ES ES95939670T patent/ES2199257T7/en active Active
- 1995-10-27 DK DK95939670.6T patent/DK0788360T5/en active
- 1995-10-27 EP EP03004280A patent/EP1312609B1/en not_active Expired - Lifetime
- 1995-10-27 AT AT95939670T patent/ATE241631T1/en active
- 1995-10-27 DE DE69534727T patent/DE69534727T2/en not_active Expired - Lifetime
- 1995-10-27 DE DE200412000025 patent/DE122004000025I1/en active Pending
- 1995-10-27 NZ NZ296717A patent/NZ296717A/en not_active IP Right Cessation
- 1995-10-27 US US08/549,318 patent/US5780454A/en not_active Expired - Lifetime
- 1995-10-27 NZ NZ337211A patent/NZ337211A/en not_active IP Right Cessation
- 1995-10-27 PT PT03004280T patent/PT1312609E/en unknown
- 1995-10-27 EP EP95939670A patent/EP0788360B3/en not_active Expired - Lifetime
- 1995-10-27 AT AT05023462T patent/ATE411324T1/en active
- 1995-10-27 EP EP08016076A patent/EP1997823A1/en not_active Withdrawn
- 1995-10-27 CA CA002203936A patent/CA2203936C/en not_active Expired - Lifetime
- 1995-10-27 DK DK03004280T patent/DK1312609T3/en active
- 1995-10-27 PT PT95939670T patent/PT788360E/en unknown
- 1995-10-27 CH CH95939670T patent/CH0788360H1/en unknown
- 1995-10-27 IL IL11579095A patent/IL115790A/en active Protection Beyond IP Right Term
- 1995-10-27 DE DE69535866T patent/DE69535866D1/en not_active Expired - Lifetime
- 1995-10-27 IL IL13383195A patent/IL133831A/en not_active IP Right Cessation
- 1995-10-27 AU AU41398/96A patent/AU710564B2/en not_active Expired
- 1995-10-27 AT AT03004280T patent/ATE314378T1/en active
- 1995-10-27 ES ES03004280T patent/ES2254803T3/en not_active Expired - Lifetime
- 1995-10-27 EP EP05023462A patent/EP1627880B1/en not_active Expired - Lifetime
- 1995-10-27 DE DE1995630936 patent/DE122004000025I2/en active Active
- 1995-10-27 CN CN2007100887250A patent/CN101077875B/en not_active Expired - Lifetime
- 1995-10-27 IL IL13772695A patent/IL137726A/en not_active IP Right Cessation
- 1995-10-27 KR KR1019970702789A patent/KR100398944B1/en not_active IP Right Cessation
- 1995-10-27 JP JP51483496A patent/JP3717934B2/en not_active Expired - Lifetime
- 1995-10-27 CN CNB951965905A patent/CN1305475C/en not_active Expired - Lifetime
-
1997
- 1997-04-23 FI FI971746A patent/FI114801B/en active Protection Beyond IP Right Term
- 1997-04-25 NO NO19971929A patent/NO310558B1/en not_active IP Right Cessation
- 1997-04-25 MX MX9703063A patent/MX9703063A/en unknown
-
1998
- 1998-02-07 HK HK98100951A patent/HK1002059A1/en not_active IP Right Cessation
- 1998-05-26 US US09/085,404 patent/US6066730A/en not_active Expired - Lifetime
-
1999
- 1999-12-30 IL IL13383199A patent/IL133831A0/en unknown
-
2000
- 2000-01-25 US US09/490,511 patent/US6297217B1/en not_active Expired - Lifetime
- 2000-08-07 IL IL13772600A patent/IL137726A0/en unknown
-
2001
- 2001-09-14 US US09/953,540 patent/US6465433B1/en not_active Expired - Lifetime
-
2002
- 2002-03-18 US US10/100,295 patent/US6548668B2/en not_active Expired - Lifetime
- 2002-04-19 US US10/125,997 patent/US6617317B1/en not_active Expired - Lifetime
-
2003
- 2003-03-19 US US10/392,165 patent/US6747150B2/en not_active Expired - Lifetime
- 2003-12-08 US US10/730,231 patent/US7119080B2/en not_active Expired - Fee Related
-
2004
- 2004-05-14 NL NL300151C patent/NL300151I2/en unknown
- 2004-05-19 FR FR04C0014C patent/FR04C0014I2/fr active Active
- 2004-06-09 LU LU91083C patent/LU91083I2/en unknown
- 2004-08-06 NO NO2004004C patent/NO2004004I2/en not_active IP Right Cessation
- 2004-11-03 FI FI20041415A patent/FI120974B/en not_active IP Right Cessation
- 2004-11-19 CY CY0400082A patent/CY2484B1/en unknown
-
2005
- 2005-10-17 US US11/252,291 patent/US20060122390A1/en not_active Abandoned
-
2006
- 2006-07-11 HK HK06107756.3A patent/HK1087714A1/en not_active IP Right Cessation
- 2006-12-20 US US11/642,372 patent/US20070282100A1/en not_active Abandoned
-
2008
- 2008-01-02 US US12/006,422 patent/US7531526B2/en not_active Expired - Lifetime
-
2009
- 2009-04-01 US US12/416,193 patent/US8003791B2/en not_active Expired - Fee Related
-
2011
- 2011-08-19 US US13/213,157 patent/US8378099B2/en not_active Expired - Fee Related
-
2013
- 2013-01-11 US US13/739,223 patent/US20130310320A1/en not_active Abandoned
-
2014
- 2014-04-08 US US14/247,711 patent/US20150072942A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2496538A1 (en) | Boronic ester and acid compounds, synthesis and uses | |
CN106008569B9 (en) | Borate as arginase inhibitor and composition and application thereof | |
KR890005031A (en) | L-dopa derivative or acid addition salt thereof, preparation method thereof and use thereof | |
JPH03503643A (en) | N-heterocyclic propylidene-1,1-bisphosphonic acid, its preparation method and pharmaceutical composition | |
CN1036207A (en) | New aspartate transcarbamylase inhibitors | |
WO2007126826A2 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20151027 |